[144] LADDER CAPITAL CORP SEC Filing

Rhea-AI Filing Summary

ImageneBio, Inc. (f/k/a Ikena Oncology, "IKNA") completed a transformational series of transactions on 07/25/2025. Director Otello Stampacchia:

• Exercised a fully-vested option for 17,520 pre-split shares (strike $1.75); after the 1-for-12 reverse split and contractual acceleration, he received 379 new common shares (Code M) held directly.
• Via Omega Fund VI, L.P., participated in the post-merger PIPE, buying 267,556 shares at $29.90 (Code P). Omega’s aggregate position rose to 454,982 shares held indirectly.

The filing confirms the closing of the merger between Ikena and Inmagene Biopharmaceuticals (two-step structure) and the corporate name change. A 1:12 reverse stock split was effected prior to the first merger step. The PIPE generated approximately $75 million gross proceeds for the issuer.

Following these actions, Stampacchia’s direct ownership is 379 shares, while his fund controls 454,982 shares, signalling continued insider commitment amid significant capital infusion and corporate re-branding.

Insights

Financial Analyst

TL;DR: Director exercised options and led a $29.9 PIPE buy; merger, reverse split and $75 m raise completed—insider alignment but dilution rises.

The Form 4 links several pivotal events: 1) completion of the Ikena–Inmagene merger, 2) 1:12 reverse split, 3) $75 m PIPE at $29.90, and 4) insider participation. Omega Fund VI’s purchase suggests confidence in the combined entity, locking in nearly 455 k shares. The $29.90 subscription price provides a reference for valuation, yet the reverse split and PIPE enlarge the share base, creating dilution for legacy holders. Acceleration of 2021 options eliminated overhang but added 379 shares. On balance, capital infusion and insider support offset dilution, making the disclosure strategically positive but only moderately impactful until market re-prices the new structure.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Rockefeller Financial LLC 45 Rockefeller Plaza Floor 5 New York NY 10111	34578	384572.00	127460976	07/30/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	08/10/2015	Stock Purchase	Issuer			20000	08/10/2015	N/A
Class A	06/10/2018	Stock Award	Issuer			1555	06/10/2018	Compensation
Class A	01/24/2019	Stock Dividend	Issuer			643	01/24/2019	N/A
Class A	02/14/2014	Stock Purchase	Issuer			3000	02/14/2014	N/A
Class A	02/18/2019	Stock Award	Issuer			5118	02/18/2019	Compensation
Class A	02/18/2019	Stock Award	Issuer			5118	02/18/2019	Compensation
Class A	02/18/2020	Stock Award	ssuer			4271	02/18/2020	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)